HHS Secretary says most restricted peptides will return to Category 1 compounding

On a podcast on February 27, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. said roughly 14 of 19 peptides on the FDA's restricted Category 2 compounding list would move back to Category 1, the designation that allows licensed compounding pharmacies to prepare a substance for patients with a prescription. He did not name the peptides, and no Federal Register notice followed right away.

Reporting since then has filled in some detail, though the process remains unfinished. Peptides expected to return to Category 1 include BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C, while melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF are expected to stay restricted ^[1]. Some reports said the affected substances were set to come off Category 2 by April 23, 2026, with the FDA's Pharmacy Compounding Advisory Committee (PCAC) scheduled to formally review the list on July 23 and 24, 2026 ^[1]. Five peptides have already left Category 2 because the companies that originally nominated them for restriction withdrew those nominations ^[1].

But a reclassification from Category 2 to Category 1 changes only whether a licensed compounding pharmacy may legally prepare a substance under sections 503A or 503B of federal drug law — it is not FDA drug approval and does not establish that a peptide is safe or effective for any specific use ^[1]. The original 2023 restrictions cited concerns about immunogenicity, manufacturing impurities, and thin clinical evidence ^[1].

That evidence gap has not closed. On June 30, 2026, the FDA posted documents ahead of the July PCAC meeting in which its own scientists flagged safety concerns and a lack of consistent data for the peptides under review, and concluded there is insufficient evidence to support changing the designation for any of the seven peptides on the agenda, which include BPC-157, TB-500, and MOTS-C ^[2]. The panel reviewing that evidence includes members with ties to the peptide industry, including people who work for companies that sell injectable peptides ^[2]. The July meeting is expected to cover uses including ulcerative colitis, wound healing, obesity, and migraines, with additional peptides to be considered at a second meeting in February 2027 ^[2].

Why it matters for patients

Since 2023, patients who wanted these peptides have often turned to unregulated online sellers marketing them as "research use only," without prescriptions, sterility testing, or medical supervision ^[1][2]. A reclassification back to Category 1 would restore a legal path through licensed compounding pharmacies, but it would not mean the FDA has reviewed and approved these peptides the way it reviews drugs like semaglutide or tirzepatide, which went through phase 1 through 3 trials ^[1]. Patients considering compounded peptides should understand that legal compounding status and proven safety or effectiveness are two different things, and that the clinical evidence for compounds such as BPC-157 and TB-500 has not changed just because the legal category might ^[1][2]. An orthopedic surgeon who reviewed the evidence, Dr. Alexander Weber, said patients ask him about peptides constantly and that his answer remains that there isn't enough data to support their use ^[2].

What happens next

The FDA's Pharmacy Compounding Advisory Committee is scheduled to formally review seven peptides on July 23 and 24, 2026, with career FDA scientists having already recommended against changing their status ^[2]. A second round covering additional peptides is planned for February 2027 ^[2]. Until the FDA formally updates its compounding lists, the legal status of these substances for pharmacy preparation has not changed, regardless of the February podcast announcement ^[1].